Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Rates of Taxane-Induced Peripheral Neuropathy Underscore Need to Tailor Treatment for Black Patients With Early Breast Cancer

October 31st 2024

Docetaxel treatment was associated with significantly less taxane-induced peripheral neuropathy vs paclitaxel in Black patients with breast cancer.

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC

October 31st 2024

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

October 30th 2024

The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.

Patients Characteristics, Sequencing Considerations Are Vital in Prostate Cancer Management

October 30th 2024

Bradley C. Carthon, MD, PhD, discusses recent data and the evolving treatment landscape in prostate cancer.

Dr Braunstein on Novel Risk Factors for Veno-Occlusive Disease Development

October 30th 2024

Marc J. Braunstein, MD, PhD, discusses VOD risk factors, management strategies, and prevention strategies in the post-HSCT hematologic malignancy setting.

Dr Sborov on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma

October 30th 2024

Douglas W. Sborov, MD, MS, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

FDA Advises Against Use of BioZorb Markers in Breast Cancer and Other Indications

October 30th 2024

The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

October 30th 2024

The FDA has received an NDA seeking the approval of a 3-month formulation of leuprolide mesylate for advanced prostate cancer.

FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia

October 29th 2024

The FDA has granted accelerated approval to asciminib for newly diagnosed, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD

October 28th 2024

Dr Gandara discusses the optimal use of liquid biopsy for patients with NSCLC and available treatment options for patients with KRAS-mutant NSCLC.

QOL Remains Key Consideration for First-Line Treatment of Anemia in Lower-Risk MDS

October 28th 2024

Jorge Cortes, MD, discusses the need to balance outcomes and quality of life in the treatment of anemia in low-risk myelodysplastic syndrome.

Dr Inra on the Role of the Surgeon in Early-Stage Lung Cancer

October 25th 2024

Matthew Lawrence Inra, MD, discusses the role of the thoracic surgeon in treatment decision-making for patients with early-stage lung cancer.

TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer

October 25th 2024

TYRA-300 was safe and produced antitumor activity in metastatic urothelial cancer harboring FGFR3 alterations.

FDA Grants Fast Track Designation to HC-7366 in Relapsed/Refractory AML

October 25th 2024

HC-7366 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory acute myeloid leukemia.

ODAC Votes on PD-1 Inhibitors Underscore Importance of Biomarker Testing in Gastric/GEJ and Esophageal Cancers

October 25th 2024

Nataliya Uboha, MD, PhD, discusses the evolving treatment landscape for patients with gastric, gastroesophageal junction, and esophageal cancers.

First-Line Ivonescimab Plus Chemotherapy Demonstrates Efficacy in Advanced TNBC

October 24th 2024

Xiaojia Wang, MD, discusses findings for ivonescimab plus chemotherapy in metastatic triple-negative breast cancer.

Addition of OFS to Endocrine Therapy Improves Survival in HR+, HER2+ Early Breast Cancer

October 24th 2024

Sung Gwe Ahn, MD, PhD, discusses survival outcomes with ovarian function suppression-based endocrine therapy based on the HERA trial in HR-positive, HER2-positive breast cancer.

FDA Grants Priority Review to TLX101-CDx for Glioma Imaging

October 24th 2024

The FDA has accepted and granted priority review to the new drug application for the glioma imaging agent TLX101-CDx.

Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer

October 24th 2024

Pembrolizumab-based combinations have been approved in Europe in 2 new indications for endometrial and cervical cancer.

Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MD

October 23rd 2024

Drs Camidge and Ney discuss Dr Ney’s journey to becoming a neurologic oncologist and his experience as a physician with Tourette syndrome.